Nuclear Receptors as Molecular Targets for Cardiometabolic and Central Nervous System Diseases

Abstract

The cloning of the first nuclear receptor cDNA encoding the human glucocorticoid receptor was described in 1985 by the team of Evans [1]. Over the next 25 years a dramatic growth of knowledge on nuclear receptors followed this discovery [2]. The knowledge on nuclear receptors has delivered novel therapies for lipid control and hormone replacement, and for management of cancers and diabetes, and millions of humans were subjected to therapies with nuclear receptor modulators over last decades